人間の血液凝固因子IXの年齢調節の遺伝的メカニズム
S Kurachi1, Y Deyashiki, J Takeshita
1Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109-0618, USA. kkurachi@umich.edu
まとめ
血液凝固は年齢とともに増加します. 研究者らは,因子IXの遺伝子発現を調節する2つの遺伝子要素,AE5'とAE3'を特定し,血液凝固の年齢関連の変化を説明した.
科学分野:
- 遺伝学 遺伝学とは
- 分子生物学は分子生物学である.
- 老化に関する研究
背景:
- 健康な個体では,血液の凝固能力は年齢とともに自然に増加します.
- 因子IXの遺伝子発現は,凝固カスケードにおいて重要な役割を果たします.
- 年齢に関連する遺伝子調節を理解することは,老化中の生理学的変化を理解するために不可欠です.
研究 の 目的:
- 人間の因子IX遺伝子発現の年齢関連変化に起因する規制要素を特定し,特徴づけること.
- 特定された元素の特定の役割が,安定した遺伝子発現を時間とともに維持することと,増加した遺伝子発現を時間とともに維持することの違いを明らかにする.
主な方法:
- トランスジェニックマウスにおけるヒト因子IX遺伝子発現の縦断分析.
- 特定のDNA調節要素 (AE5'とAE3') の識別と機能的特徴付け
主要な成果:
- フェクターIX遺伝子内で,AE5'とAE3'という2つの重要な年齢調節要素が特定されました.
- 5'上流領域に位置するAE5'は,老化安定した遺伝子発現を保証する.
- 3'未翻訳領域に位置するAE3'は,年齢に関連したメッセンジャーRNA濃度の上昇を誘発する.
結論:
- AE5'とAE3'は,因子IXの遺伝子発現の正常な年齢調節のために必要であり,十分である.
- これらの要素は協調して作用し,因子IXの遺伝子発現の自然的な年齢関連の増加を正確に再現します.
- この発見は,血液の凝固能力の年齢関連の変化を理解するための分子基盤を提供します.
関連する概念動画
Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
General Transcription Factors
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Factors Affecting Erythropoiesis
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...


